Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Generics Rule: Agency Will Scrutinize Paragraph III Switches, Troy Says

Executive Summary

Generic firms that switch Paragraph III patent certifications to Paragraph IVs once the threat of a 30-month stay of approval is gone will be subject to increased scrutiny by FDA, Chief Counsel Daniel Troy said
Advertisement

Related Content

PhRMA Wants Amended ANDAs To Trigger 30-Month Stays
PhRMA Wants Amended ANDAs To Trigger 30-Month Stays
Waxman/Hatch Reinterpretation Underpins Change In 30-Month Stay Policy
Advertisement
UsernamePublicRestriction

Register

PS042080

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel